Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review
Marie A-C Neumann, Jonas Jost, Sybille Riou, Stefanie Rungaldier, Stefan Walzer, Jörg Mahlich · 2026
Read Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review by Marie A-C Neumann, Jonas Jost, Sybille Riou, Stefanie Rungaldier, Stefan Walzer, Jörg Mahlich (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13329853.txt.
Description
Marie A-C Neumann and co-authors review how indirect comparisons of CAR-T therapies handle patient differences in a 2026 article. No head-to-head trials compare these cell therapies for large B-cell lymphoma, so indirect methods fill the gap. Such methods can mislead if key traits are not balanced.
Searches in November 2025 across three databases yielded 27 included publications. Most used matching-adjusted indirect comparisons, then score-based methods and network pooling. Adjustment ranged from none to 19 factors, most often covering age, disease severity, health status, and past treatment. Benefit outcomes were common, while harm outcomes were seldom adjusted. No study gave a full rule for picking factors, the authors note. Shared standards would aid fair comparisons.
Catalog record
| CREATOR | Marie A-C Neumann, Jonas Jost, Sybille Riou, Stefanie Rungaldier, Stefan Walzer, Jörg Mahlich |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46202 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |